Business
Supernus Announces First Quarter 2023 Financial Results
First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree® net product sales of $25.8 million, compared to
About this update from Supernus Pharmaceuticals, Inc.
[{"type":"text","content":"First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022GOCOVRI® net product sales of $26.0 million, compared to $22.6 million in first quarter 2022Excluding net product sales of Trokendi XR® in both periods, total net product sales increased 25% First quarter 2023 GAAP operating earnings of $5.2 million, compared to $2.0 million in first quarter 2022First quarter 2023 non-GAAP operating earnings of $30.5 million, compared to $28.0 million in first quarter 2022Raises full year 2023 GAAP and non-GAAP operating earnings guidance ROCKVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter of 2023, and associated Company developments. “We are pleased with the strong revenue and earnings performance despite the entry of generic Trokendi XR in the first quarter of 2023,” said Jack Khattar, President and CEO of Supernus. “Excluding Trokendi XR, first quarter 2023 net product sales increased 25%, driven by the continued adoption of Qelbree across both pediatric and adult patients and growing demand for GOCOVRI. We remain well-positioned to drive strong revenue and operating earnings growth in 2024 and beyond.” Qelbree Launch Update Total IQVIA prescriptions were 134,530 in the first quarter of 2023, an increase of 14% compared to total prescriptions of 117,635 in the fourth quarter of 2022. In March 2023, the most recent month available, total prescriptions reached 49,789.Qelbree continues to expand its base of prescribers, with approximately 19,197 prescribers in the first quarter of 2023, up from 16,822 prescribers from the fourth quarter of 2022.As previously disclosed, the Company executed a second significant pharmacy benefit manager contract, effective January 2023. We continue making progress in securing and improving managed care coverage. Product Pipeline Update SPN-830 (apomorphine infusion device) - Continuous treatment of motor fluctuations (“off” episodes) in Parkinson's disease (PD) In April 2023, the Company had a constructive meeting with the U.S. Food and Dru...